Compare CVS Health Corp (CVS) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Goldman Sachs Group Inc — how do they compare? CVS Health Corp trades at $104.32 (market cap $135.48B), while Goldman Sachs Group Inc trades at $1,142.74 (market cap $336.31B). The key difference: Goldman Sachs Group Inc is far larger — about 2.5× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | GS | |
|---|---|---|
Market Cap | $135.48B | $336.31B |
Sector | Health | Financials |
52-Week High | $106.18 | $1.14K |
52-Week Low | $58.75 | $700.41 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | 1.58% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Goldman Sachs (GS) trades at $1,045.91, down 0.88% on the day, with a bullish technical outlook and strong earnings momentum after three consecutive quarterly beats. Revenue grew to $58.28B in 2025, with net income reaching $17.18B and a net margin of 29.89%. The company is positioned to benefit from near-record M&A activity and high-profile IPOs like Anthropic, with CEO David Solomon noting investor 'greed mode' amid robust liquidity. Analysts maintain a consensus price target of $1,080 with 40% buy ratings.
The stock offers upside to the consensus target, supported by earnings growth and investment banking tailwinds, but faces risks from volatile cash flows, high leverage, and macroeconomic sensitivity. Institutional sentiment is cautiously optimistic, though negative operating cash flow and debt levels warrant monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
